Related Experiment Videos
BTS-67582 (Knoll Pharmaceuticals Co)
1Department of Pharmacology, Universite Catholique de Louvain, Cliniques Universitaires Saint Luc, Brussels, Belgium. EmiliG@war.wyeth.com
Idrugs : the Investigational Drugs Journal
|September 15, 2005
Summary
BTS-67582, a potassium channel blocker, shows promise for treating non-insulin dependent diabetes mellitus (NIDDM). Clinical trials indicate it is well-tolerated and effective in a twice-daily regimen for NIDDM patients.
Area of Science:
- Pharmacology
- Endocrinology
- Drug Development
Background:
- BTS-67582 is a morpholinoguanidine compound developed as a potassium channel blocker.
- Knoll Pharmaceuticals acquired BTS-67582 from Boots in 1995.
Purpose of the Study:
- To evaluate the efficacy and tolerability of BTS-67582 in patients with non-insulin dependent diabetes mellitus (NIDDM).
Main Methods:
- Double-blind, placebo-controlled, multicenter clinical trials.
- Involved patients diagnosed with non-insulin dependent diabetes mellitus (NIDDM).
- Utilized a twice-daily dosing regimen of BTS-67582.
Main Results:
- BTS-67582 demonstrated good tolerability in NIDDM patients.
- The drug proved effective when administered twice daily.
- No significant adverse events were highlighted in the provided text.
Conclusions:
- BTS-67582 is a well-tolerated and effective treatment option for non-insulin dependent diabetes mellitus (NIDDM).
- Further development and application in diabetes management are suggested.